Original InvestigationImpact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel
Key Words
Abbreviations and Acronyms
Cited by (0)
The TRILOGY ACS study was supported by Daiichi-Sankyo Incorporated and Eli Lilly and Company. The study sponsors had no role in the conception and design of this study or in creating the first draft of the manuscript. Employees of Eli Lilly (Drs. Winters, Duvvuru, and Jakubowski) and Cabernet Pharmaceuticals (Dr. Sundseth) participated as authors during subsequent drafts of the manuscript. All data analyses were performed independently by the Duke Clinical Research Institute. Dr. Roe receives research funding from Eli Lilly and Company, Sanofi, Daiichi-Sankyo, Janssen Pharmaceuticals, Ferring Pharmaceuticals, American College of Cardiology, American Heart Association, and the Familial Hypercholesterolemia Foundation; and consulting or honoraria from Pri-Med, AstraZeneca, Boehringer Ingelheim, Merck, Amgen, Myokardia, Eli Lilly, and Elsevier Publishers. Dr. Armstrong has received consulting fees from Eli Lilly and Company, Hoffmann-La Roche, Merck & Co., Axio Research, and Orexigen; grant support from Boehringer Ingelheim, Hoffmann-La Roche, Sanofi, Scios, Ortho Biotech, Johnson & Johnson, Janssen Pharmaceuticals, GlaxoSmithKline, Amylin Pharmaceuticals, and Merck & Co.; and payment for developing educational presentations from AstraZeneca and Eli Lilly and Company. Dr. White has received grant support from Sanofi, Eli Lilly and Company, the National Institutes of Health (NIH), Merck Sharp & Dohme, AstraZeneca, GlaxoSmithKline, Daiichi-Sankyo Pharma Development, George Institute, Omthera Pharmaceuticals, Pfizer New Zealand, Intarcia Therapeutics Inc., Elsai Inc., and DalGen Products and Services; and participates in advisory boards for AstraZeneca. Dr. Prabhakaran has received research grants from Eli Lilly and Company and the Medtronic Foundation; and honoraria from Eli Lilly and Company. Drs. Winters, Duvvuru, and Jakubowski are employees of Eli Lilly and Company. Dr. Sundseth is an employee of Cabernet Pharmaceuticals, Inc. Dr. Gurbel has served as a consultant for Daiichi-Sankyo, Eli Lilly and Company, Bayer, AstraZeneca, Boehringer Ingelheim, Merck & Co., CSL, Janssen, and New Haven Pharmaceuticals; received grants from the NIH, Daiichi-Sankyo, Merck, New Haven Pharmaceuticals, Haemonetics, Sinnowa, Coramed, and Duke Clinical Research Institute; and holds patents in the area of personalized antiplatelet therapy and interventional cardiology. Dr. Bhatt has served on the advisory boards of Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences; served on the board of directors of Boston VA Research Institute and Society of Cardiovascular Patient Care; has chaired the American Heart Association Get With The Guidelines Steering Committee; has served on the data monitoring committees of Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, and Population Health Research Institute; has received honoraria from the American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC. org), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including TRILOGY ACS), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Associate Editor; Section Editor, Pharmacology), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), WebMD (CME steering committees), and Clinical Cardiology (Deputy Editor); has received research funding from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi, The Medicines Company; has served as site co-investigator for Biotronik and St. Jude Medical; is a trustee of the American College of Cardiology; and has received unfunded research grants from FlowCo, PLx Pharma, and Takeda. Dr. Ohman has received grant support and travel expenses from Daiichi-Sankyo and Eli Lilly and Company; consulting fees from Abiomed, AstraZeneca, Biotie, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Eli Lilly and Company, Gilead Sciences, Janssen Pharmaceuticals, Liposcience, Merck & Co., Pozen, Hoffmann-La Roche, Sanofi, Stealth Peptides, The Medicines Company, Medscape, and Web MD; grant support from Gilead Sciences; and lecture fees from Gilead Sciences, Boehringer Ingelheim, and The Medicines Company. Dr. Fox has received research grants from Eli Lilly and Company, Bayer, Johnson & Johnson, and AstraZeneca; speakers bureau payments from Bayer, Johnson & Johnson, AstraZeneca, and Sanofi; and consulting/other payments from Bayer, Johnson & Johnson, AstraZeneca, Sanofi/Regeneron, Boehringer Ingelheim, GlaxoSmithKline, and Eli Lilly and Company. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Matthew Price, MD, served as Guest Editor for this paper.